Group 1 - The State Intellectual Property Office of China has granted a patent to BOE Technology Group Co., Ltd. and Beijing BOE Sensor Technology Co., Ltd. for "Detection Substrate, Its Manufacturing Method, and Flat Panel Detector," with the announcement number CN115117099B and application date in March 2021 [1] - BOE Technology Group Co., Ltd., established in 1993 and located in Beijing, primarily engages in the manufacturing of computers, communications, and other electronic devices, with a registered capital of 37,413.88 million RMB [1] - The company has invested in 73 enterprises, participated in 303 bidding projects, holds 775 trademark records, and has 5,000 patent records, along with 47 administrative licenses [1] - Beijing BOE Sensor Technology Co., Ltd., founded in 2017 and also based in Beijing, focuses on other manufacturing sectors, with a registered capital of 5,779.48 million RMB [1] - This subsidiary has invested in 4 enterprises, participated in 84 bidding projects, holds 627 patent records, and has 1 administrative license [1]

Core Viewpoint - Kangzhong Medical (688607.SH) has announced the conclusion of its fundraising projects and the allocation of surplus funds for operational and R&D purposes [1] Group 1: Fundraising Projects - The company held its 13th (temporary) meeting of the third board on December 29, 2025, to review and approve the conclusion of its initial public offering fundraising projects [1] - The projects concluded include the "Flat Panel Detector Production Base Construction Project" and the "R&D Service Center Construction Project" [1] Group 2: Surplus Fund Allocation - The total amount of surplus fundraising is 73.6495 million yuan (excluding interest and financial income) [1] - Of the total fundraising amount, 35.1485 million yuan is pending payment [1] - The company plans to allocate 30 million yuan to the "Next Generation Flat Panel Detector Design and Manufacturing Technology" R&D project and 43.6495 million yuan to permanently supplement working capital [1]

Fundraising Overview - Jiangsu Kangzhong Digital Medical Technology Co., Ltd. raised a total of RMB 511,368,684.97 through the issuance of 22,032,257 shares at a price of RMB 23.21 per share, with a net amount of RMB 447,342,486.13 after deducting issuance costs [1] - As of June 30, 2025, the company has accumulated interest income of RMB 4,418,226.16 and received investment income of RMB 24,965,294.32, totaling RMB 29,383,520.48 [1] Fund Utilization - The company has spent RMB 310,088,509.94 on fundraising projects, with RMB 21,493,944.94 spent in the current year [1] - The remaining balance in the fundraising account as of June 30, 2025, is RMB 64,994,315.57 [1] Fund Management - The company has established a fundraising management system to ensure the proper use and storage of funds, adhering to relevant laws and regulations [1] - A tripartite supervision agreement has been signed with banks and the sponsor to ensure dedicated use of the funds [1] Cash Management - The company has approved the use of up to RMB 150 million of idle fundraising for cash management, with a usage period from the approval date until the next annual board meeting in 2025 [2] - The company has invested idle funds in short-term financial products with a maturity of less than 12 months [2] Project Status - The company has not changed the use of fundraising projects or transferred any projects during the reporting period [2] - The company has experienced delays in the construction of the flat panel detector production base and R&D service center, with completion dates extended to December 2025 due to various unforeseen factors [3]

Group 1 - The core viewpoint of the news highlights the performance and market position of Yirui Technology, noting its current stock price, market capitalization, and PE ratio compared to industry averages [1] - As of March 31, 2025, Yirui Technology has 5,745 shareholders, a decrease of 883 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, and other core components, having mastered four major sensor technologies [1] Group 2 - In the latest quarterly report for Q1 2025, Yirui Technology achieved a revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, an increase of 2.74%, with a gross profit margin of 48.92% [1] - The company's rolling PE ratio is 38.27, which is lower than the industry average of 49.20 and the industry median of 36.56, ranking 77th in the industry [2] - The industry average PE ratio is 49.20, with a median of 36.56, indicating that Yirui Technology is positioned below the average in terms of valuation metrics [2]

Core Insights - The company Yirui Technology closed at 122.58 yuan, with a 1.30% increase, resulting in a rolling PE ratio of 37.39 times and a total market capitalization of 17.537 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 48.90 times and a median of 36.41 times, Yirui Technology ranks 76th [1] - As of the first quarter of 2025, 47 institutions hold shares in Yirui Technology, with a total of 82.5452 million shares valued at 9.443 billion yuan [1] Company Overview - Yirui Technology specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tube components [1] - The company has successfully mass-produced flat panel detectors and linear array detectors, mastering four sensor technologies: amorphous silicon, IGZO, CMOS, and flexible substrates [1] - These advancements are expected to enhance the company's product line, service diverse customers, and improve market competitiveness and brand influence [1] Financial Performance - In the first quarter of 2025, Yirui Technology reported revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, reflecting a year-on-year increase of 2.74% [1] - The sales gross margin stood at 48.92% [1]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][6][7]. Core Insights - The company's main business is stabilizing, with new technologies flourishing, as evidenced by the launch of various innovative products in the medical and industrial sectors [3][4]. - The company reported a revenue of 1.831 billion yuan in 2024, a slight decrease of 1.74% year-on-year, with a net profit of 465 million yuan, down 23.43% year-on-year [3]. - The company is actively expanding its product matrix and has made significant advancements in the development of new core components and X-ray comprehensive solutions [4][6]. Financial Performance Summary - In 2024, the company achieved a revenue of 1.831 billion yuan, with a gross margin of 50.11% and a net margin of 24.59% [3]. - For Q1 2025, the company reported a revenue of 482 million yuan, a year-on-year decrease of 1.92%, but a net profit increase of 2.74% to 143 million yuan [3]. - The company forecasts revenues of 2.162 billion yuan in 2025, with a projected net profit of 574 million yuan, reflecting a growth rate of 18% and 23% respectively [5][6]. Product Development and Market Position - The company has successfully launched several new products, including high-resolution detectors and various X-ray sources, enhancing its competitive edge in the market [3][4]. - The company is focusing on R&D investments in CMOS detectors, CT detectors, and photon counting detectors, which are expected to drive future growth [3][4]. - The company aims to strengthen its position as a core supplier of digital X-ray components and comprehensive solutions through continuous innovation and global business expansion [6].